Amgen and Peregrine Under StockCall Scrutiny: Pharma Stocks Deal with Drug Developments a... (of its revenue from Neupogen franchise. ...)

Amgen and Peregrine Under StockCall Scrutiny: Pharma Stocks Deal with Drug Developments and Patents

Date:2/6/2013

of its revenue from Neupogen franchise. However, the drug would go off patent protection by the end of 2013 and the loss of exclusivity is expected to affect Amgen. Neupogen faces stiff competition from the companies like Novartis in the markets outside of the U.S. and these competing companies may launch their products in the U.S., causing further damage. However, the company has somewhat strong drug candidates including AMG145, a cholesterol drug candidate.

Amgen stock grew over 25 percent in the past 12 months. It also offers good dividend yield of 2.17 percent. The company is likely to increase its dividend in the future, thus offering good returns to the investors. Amgen is also growing through acquisitions as it recently completed the purchase of Icelandic company decode Genetics.

Peregrine Struggles with Cancer Drug Development

Peregrine Pharmaceuticals Inc. specializes in developing therapies for viral infections. It also develops treatments for cancers. It is currently engaged in developing treatment for non-small cell lung cancer. If successful, the company will make big fortunes as non-small cell lung cancer accounts for about 80 percent of lung cancer cases. However, the company does not have very solid track record. The drug candidate bavituximab has been controversial as it led to the stock's massive tumble in September 2012. Sign up to download the free technical analysis on Peregrine Pharmaceuticals at

http://www.StockCall.com/PPHM020613.pdf

Peregrine is a small company with the market capitalization of less than $300 million. The stock is quite volatile as well. The company is currently looking to get past the phase II for bavituximab. Overall, the stock may be held if it is already in your portfolio. On the upside, the stock is currently trading about 50 percent below its 52-week high, thus in case of positive news on its
'/>"/>

SOURCE StockCall.com
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3
Related medicine technology :

1. Amgen to Acquire Mustafa Nevzat, a Leading Privately Held Turkish Pharmaceutical Company
2. Four Californians Selected As Breakaway from Cancer® Champions To Be Honored During Amgen Tour of California
3. Amgen to Present at the Baird Growth Stock Conference
4. Amgen To Provide Testimony At FDA Stakeholder Hearing On Biosimilars
5. Amgens BiTE® Antibody Blinatumomab (AMG 103) Achieved High Rate of Complete Response in Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
6. Amgen Announces Top-Line Results Of Phase 3 Sensipar®/Mimpara® EVOLVE™ Trial
7. Amgen Completes Acquisition of Mustafa Nevzat Pharmaceuticals
8. Amgen Completes Acquisition of KAI Pharmaceuticals
9. Amgens Second Quarter 2012 Revenues Increased 13 Percent To $4.5 Billion And Adjusted Earnings Per Share (EPS) Increased 34 Percent To $1.83
10. Amgen Announces Termination Of Ganitumab Phase 3 Study For Futility In Metastatic Pancreatic Cancer
11. Amgen To Present At The Baird Healthcare Conference

Post Your Comments:

(Date:6/18/2013)... -- New-generation electronic designs are focused on rugged ... circuitry is increasing the number of functions it ... performs at. Connecting cables from the active elements ... as cameras or detectors, must be small, flexible ... custom cable designs for high-quality signal and EMI ...

(Date:6/18/2013)... And EMERYVILLE, Calif. , June ... final results today from a Phase 2/3 clinical ... demonstrating a statistically significant improvement in levodopa-induced dyskinesia ... week 8 versus placebo in the Unified Dyskinesia ... formulation of amantadine intended for once-nightly administration that ...

(Date:6/18/2013)... 18, 2013 Polymer Technology Systems, Inc. ... Health Group to integrate the CardioChek ® ... administered by health systems across the country. The ... and distributed through Hanson Medical Systems , ... cholesterol, LDL cholesterol, triglycerides, and glucose. ...

Breaking Medicine Technology:Omnetics Circular Connectors Offer Both Micro and Nano Interconnects for Highly Portable Electronic Systems, Meeting the Needs of Designers Looking for Size Reduction Options and Cable Flexibility 2 Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinson's Disease 2 Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinson's Disease 3 Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinson's Disease 4 Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinson's Disease 5 Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinson's Disease 6 Polymer Technology Systems, Inc. to Provide Point-of-Care Lipid Testing to Aegis Health Group's Hospital Clients 2 Polymer Technology Systems, Inc. to Provide Point-of-Care Lipid Testing to Aegis Health Group's Hospital Clients 3

[0] Omnetics Circular Connectors Offer Both Micro and Nano Interconnects for Highly Portable Electronic Systems, Meeting the Needs of Designers Looking for Size Reduction Options and Cable Flexibility [0] Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinson's Disease [0] Polymer Technology Systems, Inc. to Provide Point-of-Care Lipid Testing to Aegis Health Group's Hospital Clients

... CARLOS, Calif., Sept. 21 NeurogesX, Inc.,(Nasdaq: ... enrollment in study,C119, a second Phase 3 clinical ... treatment of painful HIV-distal sensory polyneuropathy,(HIV-DSP). NGX-4010 is ... Previously completed Phase 3 trials demonstrated that a,single, ...

... the American Journal of Nephrology -, DEERFIELD, Ill., ... its Phase III data on VAPRISOL was published in,the ... this study,VAPRISOL showed a significant increase in serum sodium ... that,occurs when the body,s sodium level falls below normal. ...

Cached Medicine Technology:NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy 2 NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy 3 NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy 4 Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia 2 Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia 3 Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia 4 Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia 5

NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia

(Date:6/19/2013)... CO (PRWEB) June 19, 2013 ... marketing company for coaches, announced today its affiliation ... means CoachingWebsites will offer exclusive websites and marketing ... partnerships. , “This new partnership with Active Intelligence ... their business to its fullest,” says Greer Van ...

(Date:6/19/2013)... 2013 The Mesothelioma Victims Center ... of the 2500 to 3000 citizens, who will be ... this year, about one third will be US Navy ... with this asbestos exposure form of cancer, or their ... to the nations most skilled mesothelioma compensation settlement attorneys, ...

(Date:6/19/2013)... Middle market merger and acquisition (M&A) activity ... cash rich buyers seek to place their capital in ... transactions have a good deal in common. The acquirer ... and quality of the target company’s earnings. Potential risks ... diligence involves a middle market company, whose value consists ...

(Date:6/18/2013)... 19, 2013 oBand Surgery Centers, a ... holding complimentary weight loss seminars in Los Angeles this ... be accessed at their official website. oBand Surgery Centers ... time. Their highly skilled panel of surgeons and dedicated ... , A senior executive working with oBand Surgery Centers ...

(Date:6/18/2013)... Philadelphia, PA, June 19, 2013 Recent studies ... coverage of bullying-related suicide among young people, led ... to assemble an expert panel to focus on ... about the complex relationship between youth involvement in ... Bullying among youth is a significant public health ...

Breaking Medicine News(10 mins):Health News:CoachingWebsites (Websites for Coaches) Announces Their Partnership With Active Intelligence, LLC 2 Health News:Mesothelioma Victims Center Urges US Navy Veterans Diagnosed With Mesothelioma To Call Them For Instant Access To The Nation's Top Asbestos Lawyers-Better Compensation 2 Health News:Mesothelioma Victims Center Urges US Navy Veterans Diagnosed With Mesothelioma To Call Them For Instant Access To The Nation's Top Asbestos Lawyers-Better Compensation 3 Health News:Newport Board Group, a National Business Advisory Firm of CEOs Cautions Buyers on 5 Questions to Ask Before Acquiring a Technology-Based Middle Market Company 2 Health News:Newport Board Group, a National Business Advisory Firm of CEOs Cautions Buyers on 5 Questions to Ask Before Acquiring a Technology-Based Middle Market Company 3 Health News:oBand Surgery Centers Will Hold Complimentary Weight Loss Seminars in Los Angeles in June 2 Health News:Bullying and suicide among youth is a public health problem 2

[0] CoachingWebsites (Websites for Coaches) Announces Their Partnership With Active Intelligence, LLC [0] Mesothelioma Victims Center Urges US Navy Veterans Diagnosed With Mesothelioma To Call Them For Instant Access To The Nation's Top Asbestos Lawyers-Better Compensation [0] Newport Board Group, a National Business Advisory Firm of CEOs Cautions Buyers on 5 Questions to Ask Before Acquiring a Technology-Based Middle Market Company [0] oBand Surgery Centers Will Hold Complimentary Weight Loss Seminars in Los Angeles in June [0] Bullying and suicide among youth is a public health problem

... May 11 /PRNewswire-Asia-FirstCall/ -- Mindray Medical,International Limited (NYSE: ... worldwide announced today its selected unaudited,financial results for the first ... Highlights for First Quarter 2009, -- First ... 53.5% over the first ...

... Trust Incorporated (NYSE: HR ) today announced its ... 2009. This dividend, in the amount of $0.385 per ... record on May 22, 2009. The total dividend of ... operations determined in accordance with GAAP. The Company,s cash ...

... Health Care Costs Over Next Ten Years, Provides Significant ... Year WASHINGTON, May 11 Today, key stakeholders in ... House to announce their commitment to achieving a sharp ... to prioritize preventive care, manage chronic illnesses, curtail unnecessary ...

... will be lethality of infection going forward, experts say , , ... epidemic does have pandemic potential and is likely to be ... of its spread, a new expert analysis concludes. , The ... unreported -- swine flu infections in Mexico, the outbreak,s epicenter, ...

... Call on May 14, 2009 NEW HAVEN, Conn., May 11 ... announced financial results for the first quarter of 2009. , ... $4.3 million, or $0.54 per share, for the quarter ended March ... $1.14 per share, for the same 2008 period. Weighted-average common ...

... prominently featured on the HRS 2009 programST. LOUIS, May ... said today that the Heart Rhythm 2009 formal program ... Niobe system is either featured or discussed regarding the ... efficacy data on the use of Stereotaxis, partnered magnetic ...

Mindray Announces First Quarter 2009 Financial Results Healthcare Realty Trust Announces First Quarter Dividend Kaine Lauds President Obama's Agreement With Health Care Industry Groups to Reduce Health Care Costs Study Supports Swine Flu's Pandemic Potential Vion Pharmaceuticals Reports 2009 First Quarter Results Stereotaxis' Market Leadership Highlighted at Heart Rhythm 2009

... is a completely new concept ... use of optic technology for ... applying touch-less vibration system (Patent ... ergonomic user friendly, novel design ...

... A human blood based control designed ... needs, from Point of Care Testing (POCT) ... labs. GlycoHemosure is intended as a basic ... procedures for the quantitation of hemoglobin A1c. ...

SPOT RT KE and RT SE digital camera lines provide maximum performance in a mid-line scientific camera system....

... ResMeds premium APAP device in the S8 ... patients pressure needs on a breath-by-breath basis. ... fully integrated humidification and also include remote ... patients time by reducing medical visits. Like ...

Medicine Products:

Wizard Vortex GlycoHemosure Hemoglobin A1c Control SPOT RT ResMed S8 AutoSet Vantage